Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | C1S | P09871 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5097228 | 0.75 | MAPT (0.47) | MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL17275595 | 0.73 | RAPGEF4 (0.45) | SMN1; SMN2HCAR2 | |
| SCHEMBL5097575 | 0.73 | HTR6 (0.49) | HTR6MAPTALDH1A1SMN1; SMN2GFER | |
| SCHEMBL20694910 | 0.71 | ADAMTS5 (0.43) | MAPTGFERTP53 | |
| SCHEMBL27506891 | 0.70 | HTR6 (0.83) | HTR6ALDH1A1 | |
| SCHEMBL28740894 | 0.70 | HTR6 (0.43) | HTR6AKR1C3C1SHCAR2 | |
| SCHEMBL2502244 | 0.70 | KDM4E (0.36) | MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL8322575 | 0.68 | SOS1 (0.42) | HTR6CYP3A4ALDH1A1CCR1 | |
| SCHEMBL28979 | 0.68 | HTR2A (0.49) | MAPTALDH1A1 | |
| SCHEMBL1856356 | 0.68 | KDM4E (0.46) | CYP3A4MAPTALDH1A1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925755-B1 | NEUROPROTECTIVE AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV WAYNE STATE (US) | 2021-09-08 | — | — | EP | disclosed |
| US-10874669-B2 | Neuroprotective agents for treatment of neurodegenerative diseases | WAYNE STATE UNIVERSITY (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190076426-A1 | NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | WAYNE STATE UNIVERSITY | 2019-03-14 | — | — | US | disclosed |
| US-20190038622-A1 | NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | WAYNE STATE UNIVERSITY | 2019-02-07 | — | — | US | disclosed |
| US-10125127-B2 | Neuroprotective agents for treatment of neurodegenerative diseases | WAYNE STATE UNIVERSITY (US) | 2018-11-13 | — | — | US | disclosed |
| US-20150299180-A1 | NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | WAYNE STATE UNIVERSITY (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2925755-A1 | NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | Wayne State University (US) | 2015-10-07 | — | — | EP | disclosed |
| US-9034877-B2 | Bifunctional/polyfunctional dopamine D2/D3 agonist as neuroprotective agents for treatment of neurodegenerative diseases | WAYNE STATE UNIVERSITY (US) | 2015-05-19 | — | — | US | disclosed |
| WO-2014085600-A1 | NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | WAYNE STATE UNIVERSITY (US) | 2014-06-05 | — | — | WO | disclosed |
| US-20120108815-A1 | BIFUNCTIONAL/POLYFUNCTIONAL DOPAMINE D2/D3 AGONIST AS NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | WAYNE STATE UNIVERSITY (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2010123995-A1 | BIFUNCTIONAL/POLYFUNCTIONAL DOPAMINE D2/D3 AGONIST AS NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | WAYNE STATE UNIVERSITY (US) | 2010-10-28 | — | — | WO | disclosed |
| CN-1257892-C | New indole derivatives with 5-HT6 receptor affinity | HOFFMANN LA ROCHE (CH) | 2006-05-31 | — | — | CN | disclosed |
| CN-1527816-A | Novel indole derivatives having 5-HT 6 receptor affinity | - | 2004-09-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299180-A1 | NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | RTN4, NR4A1, NR4A3 | HTR6 397/4885CYP3A4 1849/4885ROCK2 4317/4885 |
| US-20190076426-A1 | NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | SMN1; SMN2, PARK7, SNCA | HTR6 1058/4885CYP3A4 4526/4885ROCK2 2090/4885 |
| US-20190038622-A1 | NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | SMN1; SMN2, PARK7, SNCA | HTR6 1058/4885CYP3A4 4526/4885ROCK2 2090/4885 |
| US-10125127-B2 | Neuroprotective agents for treatment of neurodegenerative diseases | RTN4, NR4A1, NR4A3 | HTR6 397/4885CYP3A4 1849/4885ROCK2 4317/4885 |
| US-20120108815-A1 | BIFUNCTIONAL/POLYFUNCTIONAL DOPAMINE D2/D3 AGONIST AS NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | DRD3, DRD2, SLC6A3 | HTR6 166/4885CYP3A4 4259/4885ROCK2 2425/4885 |
| US-10874669-B2 | Neuroprotective agents for treatment of neurodegenerative diseases | SMN1; SMN2, PARK7, SNCA | HTR6 1058/4885CYP3A4 4526/4885ROCK2 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.